Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for NXP200 (BRAF Inhibitor) in BRAF-Mutated Solid Tumors. The expected timing is based on the latest available company guidance and may change.
08/04/26:- NXP200 Ph1b ongoing; ESMO data Oct 2026. U.S. IND submission expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.